CAMBRIDGE, Mass.--(BUSINESS WIRE)--Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-like Receptors (TLR), today announced that it will present a corporate overview at the 11th Annual BIO CEO & Investor Conference on Monday, February 9 at 10:30 a.m. (ET) at the Waldorf=Astoria hotel in New York City.
